ClinicalTrialsFinder
RecruitingNot ApplicableNCT03686709

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Sponsor

University of Tennessee

Enrollment

20 participants

Start Date

Jun 19, 2018

Study Type

INTERVENTIONAL

Conditions

Hepatocellular CarcinomaRadiation Exposure

Summary

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
  • Must be able to schedule and tolerate additional PET/CT imaging following therapy
  • Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.

Exclusion Criteria4

  • Patients that are not candidates for Y90 radioembolization therapy
  • Patients that cannot tolerate additional imaging procedures following therapy
  • Patients that cannot tolerate the additional blood draws required for this study
  • Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Interventions

DIAGNOSTIC_TESTPost therapy PET/CT Imaging

whole-body PET/CT following Y90 radioembolization

Locations(1)

University of Tennessee Medical Center

Knoxville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03686709

Related Trials

Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients

NCT056298451 location

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors

NCT060775911 location

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT054683592 locations

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

NCT0552895214 locations

Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

NCT0679611410 locations